IN the know

IN the know

Fostering greater collaboration in rare disease research

By Becca Bull, RARE Revolution

16 March 2026

IN the know

Do you have a clear communication plan for study/trial awareness and recruitment?

By Emma Bishop, RARE Revolution

9 March 2026

IN the know

Rare Disease Day: after the dust settles

By Nicola Miller, RARE Revolution

9 March 2026

IN the know

Silent absence of research in treatment journeys

By Keith Berelowitz, trialport

9 March 2026

IN the know

From ‘high conviction’ to patient impact: inside BIA’s UK Biotech Financing 2025 report – Part two

By Nicola Miller, RARE Revolution

2 March 2026

IN the know

Withdrawal of USAID is fanning winds of entrepreneurial change across Africa

By CONTRIBUTOR

23 February 2026

IN the know

Rethinking consent: The unresolved challenge of genomic newborn screening

By Amy Gaviglio, Connetics Consulting

23 February 2026

IN the know

Do you understand the difference between study/trial awareness and study/trial recruitment?

By Emma Bishop, RARE Revolution

23 February 2026

IN the know

From ‘high conviction’ to patient impact: inside BIA’s UK Biotech Financing 2025 report – Part one

By Nicola Miller, RARE Revolution

23 February 2026

IN the know

Accessing life-sustaining equipment: a silent systemic gap

By CONTRIBUTOR

23 February 2026

IN the know

Who do you feel is responsible for study/trial awareness and recruitment?

By Emma Bishop, RARE Revolution

16 February 2026

IN the know

Singing for your dinner

By Daniel Lewi, The CATS Foundation

16 February 2026

IN the know

How important is partnering with patient groups to the successes within your company?

By Emma Bishop, RARE Revolution

9 February 2026

IN the know

What do you feel is the most pressing priority for successful rare disease drug discovery in 2026?

By Emma Bishop, RARE Revolution

2 February 2026

IN the know

Key challenges in transition: how young people with rare diseases are falling through the net

By Becky Pender, RARE Revolution

2 February 2026

IN the know

Rare Revolution poll finds quality of life matters hugely for rare disease individuals and families, and industry could do more

By Julie Penfold, RARE Revolution

2 February 2026

IN the know

Following an unsettled year how do you feel about the future of rare disease pipelines?

By Emma Bishop, RARE Revolution

26 January 2026

« Previous 1 2 3 4 … 7 Next »